RDNT

RDNT's advanced imaging mix is expanding. I think this will continue to support its improving revenue quality and margins. RDNT's joint ventures across healthcare systems also help it deepen its integration across customers' workflows. DeepHealth is RDNT's second growth leg, as it pairs external software sales with internal workflow efficiencies.

RadNet tops Q2 estimates as advanced imaging and Digital Health growth accelerate, prompting a higher 2026 Imaging Center outlook.

RadNet NASDAQ: RDNT reported record quarterly revenue and adjusted EBITDA for the second quarter of 2026, supported by higher imaging volumes, acquisitions, a shift toward advanced imaging procedures and growth in its Digital Health segment.

The headline numbers for RadNet (RDNT) give insight into how the company performed in the quarter ended June 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Total Company Revenue increased 25.0% to a quarterly record of $622.7 million in the second quarter of 2026 from $498.2 million in the second quarter of 2025 Revenue from the Digital Health reportable segment (inclusive of intersegment revenue) increased 56.5% to a quarterly record of $32.4 million in the second quarter of 2026 from $20.7 million in the second quarter of 2025; Annual Recurring Revenue ( 4) (ARR) increased from $53.5 million at June 30, 2025 to $105.5 million at June 30, 2026 and sequentially increased from $96.9 million at March 31, 2026 Total Company Adjusted EBITDA ( 1) was a quarterly record of $99.7 million in the second quarter of 2026 as compared with $81.2 million in the second quarter of 2025, an increase of 22.7%; Digital Health reportable segment Adjusted EBITDA ( 1) was $2.5 million in the second quarter of 2026 compared with $3.4 million in the second quarter of 2025, the result of continued infrastructure investments to fuel growth Imaging Center Segment Adjusted EBITDA ( 1) margin increased by 17 basis points to 16.1% in the second quarter of 2026 from 16.0% in the second quarter of 2025 Adjusting for unusual or one-time items, Adjusted Earnings ( 3) was $23.2 million and Adjusted Earnings Per Share ( 3) was $0.29 for the second quarter of 2026 as compared with Adjusted Earnings ( 3) of $25.7 million and Adjusted Earnings Per Share ( 3) of $0.34 for the second quarter of 2025   As a percentage of total procedural volumes, advanced imaging increased by 238 basis points to 29.9% in the second quarter of 2026 from 27.5% in the second quarter of 2025 In the second quarter of 2026, aggregate advanced imaging (MRI, CT and PET/CT) procedural volumes increased 21.2% and same-center advanced imaging procedural volumes increased 9.6% as compared with the second quarter of 2025 As of June 30, 2026, balance sheet cash was $726.3 million and Net Debt to Adjusted EBITDA ( 1) Ratio ( 5 ) was 1.8x RadNet revises full-year 2026 Imaging Center guidance levels with increases to Revenue, Adjusted EBITDA ( 1) and Free Cash Flow ( 2 ) and reaffirms all Digital Health guidance ranges LOS ANGELES, Aug. 09, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT) (“RadNet” or the “Company”), a national leader in providing high-quality, cost-effective, fixed-site outpatient diagnostic imaging services through a network of 442 owned and operated outpatient imaging centers, today reported financial results for its second quarter of 2026. Dr. Howard Berger, President and Chief Executive Officer of RadNet, commented, “The Imaging Center and Digital Health reportable operating segments continue to demonstrate strong growth and achieve record quarterly results.

Besides Wall Street's top-and-bottom-line estimates for RadNet (RDNT), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended June 2026.

SOMERVILLE, Mass., July 30, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a global leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), today announced FDA 510(k) clearance for DeepHealth Breast Ultrasound,1 an AI-powered solution that brings greater standardization, clinical accuracy and efficiency to breast ultrasound imaging.

LOS ANGELES, July 22, 2026 (GLOBE NEWSWIRE) -- RadNet, Inc. (NASDAQ: RDNT), a national leader in providing high-quality, cost-effective diagnostic imaging services through a network of owned and operated outpatient imaging centers and digital health solutions, announced today that it will host a conference call to discuss its second quarter 2026 financial results on Monday, August 10, 2026 at 7:30 a.m. Pacific Time (10:30 a.m. Eastern Time).

RadNet's DeepHealth gains FDA clearances for AI breast imaging tools that assess cardiovascular risk and compare prior mammograms.

SOMERVILLE, Mass., June 25, 2026 (GLOBE NEWSWIRE) -- DeepHealth, Inc., a leader in AI-powered health informatics and a wholly owned subsidiary of RadNet, Inc. (NASDAQ: RDNT), announces it has received FDA 510(k) clearances for two new Breast Suite1 functionalities: Breast Arterial Calcification (BAC) Assessment, a tool applied to standard screening mammograms that automatically identifies breast arterial calcifications, a potential early indicator of cardiovascular disease;2 Prior exam integration into ProFound Pro, which enables automatic processing of prior and current studies to track prior lesions and distinguish new lesions, with the goal of improving cancer detection rates and reducing recalls.